AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 1.
Searle
Benjamin
B
Thomson Scientific, 77 Hatton Garden, London, EC1N 8JS, UK. benjamin.searle@thomson.com
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors; D002986:Clinical Trials as Topic; D006801:Humans; D000077146:Irinotecan; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000188:drug therapy*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D018797:Cell Cycle Proteins; D000081082:Phosphoinositide-3 Kinase Inhibitors; D000077146:Irinotecan; C068619:CDC7 protein, human; C089212:protein kinase D; D053614:Janus Kinase 2; D017346:Protein Serine-Threonine Kinases; D011493:Protein Kinase C; D002166:Camptothecin